7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A detailed look at the legal status of compounding lisdexamfetamine (Vyvanse), including FDA regulations under 503A/503B, DEA Schedule II restrictions, and state-level rules.
A detailed comparison of how the FDA and EMA evaluated, labeled, and monitor lisdexamfetamine (Vyvanse), including approval dates, label differences, post-market surveillance programs, and what each means for prescribers and patients.
A clinical deep-dive into Vyvanse (lisdexamfetamine) FAERS adverse event reports, FDA label warnings, and post-market surveillance data, reviewed by the HealthRX medical team.
A complete timeline of Vyvanse (lisdexamfetamine) FDA approvals, label expansions, safety updates, and generic entry, with primary-source citations from Drugs@FDA and PubMed.
A comprehensive review of lisdexamfetamine (Vyvanse) regulatory status worldwide, including FDA approval history, EMA authorization, scheduling classifications, label updates, and ongoing safety monitoring.
A detailed review of Vyvanse (lisdexamfetamine) patent litigation, Hatch-Waxman challenges, FDA approval timeline, and the path to generic availability.
A comprehensive look at lisdexamfetamine (Vyvanse) regulatory history, current FDA label, post-market safety data, and what the pipeline holds for next-generation ADHD and BED pharmacotherapy.